VIB VERMOEGEN AG (VIH1.DE) Stock Fundamental Analysis
Europe - FRA:VIH1 - DE000A2YPDD0 - Common Stock
11.35 EUR
+0.25 (+2.25%)
Overall VIH1 gets a fundamental rating of 5 out of 10. We evaluated VIH1 against 74 industry peers in the Real Estate Management & Development industry. VIH1 has a medium profitability rating, but doesn't score so well on its financial health evaluation. VIH1 scores decently on growth, while it is valued quite cheap. This could make an interesting combination.
1. Profitability
1.1 Basic Checks
In the past year VIH1 was profitable.
In the past year VIH1 had a positive cash flow from operations.
Each year in the past 5 years VIH1 has been profitable.
In the past 5 years VIH1 always reported a positive cash flow from operatings.
1.2 Ratios
With a decent Return On Assets value of 1.69%, VIH1 is doing good in the industry, outperforming 60.81% of the companies in the same industry.
VIH1's Return On Equity of 3.99% is in line compared to the rest of the industry. VIH1 outperforms 59.46% of its industry peers.
VIH1 has a Return On Invested Capital of 3.21%. This is in the better half of the industry: VIH1 outperforms 68.92% of its industry peers.
The Average Return On Invested Capital over the past 3 years for VIH1 is in line with the industry average of 3.87%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.69% | ||
| ROE | 3.99% | ||
| ROIC | 3.21% |
ROA(3y)4.03%
ROA(5y)3.75%
ROE(3y)8.99%
ROE(5y)8.64%
ROIC(3y)4.05%
ROIC(5y)4.34%
1.3 Margins
The Profit Margin of VIH1 (34.63%) is better than 74.32% of its industry peers.
In the last couple of years the Profit Margin of VIH1 has declined.
The Operating Margin of VIH1 (70.15%) is better than 90.54% of its industry peers.
VIH1's Operating Margin has declined in the last couple of years.
With a decent Gross Margin value of 78.88%, VIH1 is doing good in the industry, outperforming 67.57% of the companies in the same industry.
In the last couple of years the Gross Margin of VIH1 has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 70.15% | ||
| PM (TTM) | 34.63% | ||
| GM | 78.88% |
OM growth 3Y-3.76%
OM growth 5Y-2.01%
PM growth 3Y5.97%
PM growth 5Y-12.98%
GM growth 3Y-2.37%
GM growth 5Y-0.86%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so VIH1 is destroying value.
Compared to 1 year ago, VIH1 has about the same amount of shares outstanding.
The number of shares outstanding for VIH1 has been increased compared to 5 years ago.
VIH1 has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.72, we must say that VIH1 is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.72, VIH1 is not doing good in the industry: 62.16% of the companies in the same industry are doing better.
VIH1 has a debt to FCF ratio of 10.39. This is a negative value and a sign of low solvency as VIH1 would need 10.39 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 10.39, VIH1 is in the better half of the industry, outperforming 71.62% of the companies in the same industry.
VIH1 has a Debt/Equity ratio of 1.01. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.01, VIH1 is in line with its industry, outperforming 40.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.01 | ||
| Debt/FCF | 10.39 | ||
| Altman-Z | 0.72 |
ROIC/WACC0.72
WACC4.49%
2.3 Liquidity
VIH1 has a Current Ratio of 1.03. This is a normal value and indicates that VIH1 is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.03, VIH1 perfoms like the industry average, outperforming 44.59% of the companies in the same industry.
A Quick Ratio of 1.03 indicates that VIH1 should not have too much problems paying its short term obligations.
VIH1 has a Quick ratio of 1.03. This is in the better half of the industry: VIH1 outperforms 63.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.03 | ||
| Quick Ratio | 1.03 |
3. Growth
3.1 Past
The earnings per share for VIH1 have decreased strongly by -72.11% in the last year.
The earnings per share for VIH1 have been decreasing by -13.74% on average. This is quite bad
VIH1 shows a small growth in Revenue. In the last year, the Revenue has grown by 4.50%.
Measured over the past years, VIH1 shows a small growth in Revenue. The Revenue has been growing by 2.78% on average per year.
EPS 1Y (TTM)-72.11%
EPS 3Y0.35%
EPS 5Y-13.74%
EPS Q2Q%15.94%
Revenue 1Y (TTM)4.5%
Revenue growth 3Y0.51%
Revenue growth 5Y2.78%
Sales Q2Q%26.78%
3.2 Future
The Earnings Per Share is expected to grow by 11.54% on average over the next years. This is quite good.
VIH1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.81% yearly.
EPS Next Y10.47%
EPS Next 2Y11.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year13.92%
Revenue Next 2Y10.81%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 10.41 indicates a reasonable valuation of VIH1.
77.03% of the companies in the same industry are more expensive than VIH1, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.28, VIH1 is valued rather cheaply.
With a Price/Forward Earnings ratio of 5.20, the valuation of VIH1 can be described as very cheap.
Based on the Price/Forward Earnings ratio, VIH1 is valued cheaper than 95.95% of the companies in the same industry.
VIH1's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 33.61.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.41 | ||
| Fwd PE | 5.2 |
4.2 Price Multiples
94.59% of the companies in the same industry are more expensive than VIH1, based on the Enterprise Value to EBITDA ratio.
86.49% of the companies in the same industry are more expensive than VIH1, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.78 | ||
| EV/EBITDA | 6.52 |
4.3 Compensation for Growth
VIH1's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
VIH1 has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1
PEG (5Y)N/A
EPS Next 2Y11.54%
EPS Next 3YN/A
5. Dividend
5.1 Amount
With a yearly dividend of 0.36%, VIH1 is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 7.45, VIH1 has a dividend in line with its industry peers.
With a Dividend Yield of 0.36, VIH1 pays less dividend than the S&P500 average, which is at 2.36.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.36% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y11.54%
EPS Next 3YN/A
FRA:VIH1 (11/10/2025, 7:00:00 PM)
11.35
+0.25 (+2.25%)
Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryReal Estate Management & Development
Earnings (Last)
Earnings (Next)
Inst Owners0.92%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap375.12M
Revenue(TTM)104.37M
Net Income(TTM)36.14M
Analysts82.86
Price Target11.73 (3.35%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.36% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.41 | ||
| Fwd PE | 5.2 | ||
| P/S | 3.59 | ||
| P/FCF | 3.78 | ||
| P/OCF | 3.78 | ||
| P/B | 0.41 | ||
| P/tB | 0.43 | ||
| EV/EBITDA | 6.52 |
EPS(TTM)1.09
EY9.6%
EPS(NY)2.18
Fwd EY19.23%
FCF(TTM)3.01
FCFY26.48%
OCF(TTM)3.01
OCFY26.48%
SpS3.16
BVpS27.39
TBVpS26.47
PEG (NY)1
PEG (5Y)N/A
Graham Number25.92
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.69% | ||
| ROE | 3.99% | ||
| ROCE | 3.73% | ||
| ROIC | 3.21% | ||
| ROICexc | 3.25% | ||
| ROICexgc | 3.3% | ||
| OM | 70.15% | ||
| PM (TTM) | 34.63% | ||
| GM | 78.88% | ||
| FCFM | 95.17% |
ROA(3y)4.03%
ROA(5y)3.75%
ROE(3y)8.99%
ROE(5y)8.64%
ROIC(3y)4.05%
ROIC(5y)4.34%
ROICexc(3y)4.4%
ROICexc(5y)4.63%
ROICexgc(3y)4.52%
ROICexgc(5y)4.7%
ROCE(3y)4.69%
ROCE(5y)5.03%
ROICexgc growth 3Y-10.75%
ROICexgc growth 5Y-3.98%
ROICexc growth 3Y-11.34%
ROICexc growth 5Y-4.36%
OM growth 3Y-3.76%
OM growth 5Y-2.01%
PM growth 3Y5.97%
PM growth 5Y-12.98%
GM growth 3Y-2.37%
GM growth 5Y-0.86%
F-Score4
Asset Turnover0.05
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.01 | ||
| Debt/FCF | 10.39 | ||
| Debt/EBITDA | 4.3 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 46.63% | ||
| Profit Quality | 274.83% | ||
| Current Ratio | 1.03 | ||
| Quick Ratio | 1.03 | ||
| Altman-Z | 0.72 |
F-Score4
WACC4.49%
ROIC/WACC0.72
Cap/Depr(3y)0.86%
Cap/Depr(5y)88.75%
Cap/Sales(3y)0.31%
Cap/Sales(5y)0.52%
Profit Quality(3y)144.88%
Profit Quality(5y)156.35%
High Growth Momentum
Growth
EPS 1Y (TTM)-72.11%
EPS 3Y0.35%
EPS 5Y-13.74%
EPS Q2Q%15.94%
EPS Next Y10.47%
EPS Next 2Y11.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.5%
Revenue growth 3Y0.51%
Revenue growth 5Y2.78%
Sales Q2Q%26.78%
Revenue Next Year13.92%
Revenue Next 2Y10.81%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.54%
EBIT growth 3Y-3.27%
EBIT growth 5Y0.72%
EBIT Next Year69.35%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y21.92%
FCF growth 3Y6.73%
FCF growth 5YN/A
OCF growth 1Y22%
OCF growth 3Y6.76%
OCF growth 5Y5.7%
VIB VERMOEGEN AG / VIH1.DE FAQ
What is the fundamental rating for VIH1 stock?
ChartMill assigns a fundamental rating of 5 / 10 to VIH1.DE.
What is the valuation status for VIH1 stock?
ChartMill assigns a valuation rating of 8 / 10 to VIB VERMOEGEN AG (VIH1.DE). This can be considered as Undervalued.
What is the profitability of VIH1 stock?
VIB VERMOEGEN AG (VIH1.DE) has a profitability rating of 6 / 10.
What is the earnings growth outlook for VIB VERMOEGEN AG?
The Earnings per Share (EPS) of VIB VERMOEGEN AG (VIH1.DE) is expected to grow by 10.47% in the next year.